Incomplete Invention of Drugs
Recent Patents on Inflammation & Allergy Drug Discovery · 2007
DOI: 10.2174/187221307779815138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Recent Patents on Inflammation & Allergy Drug Discovery, 2007. Verfasst von Tomoyuki Hisa. Beteiligte Einrichtung: University of Tokyo, Rm670, Bldg4, RCAST, 4-6-1 Komaba, Meguro, Tokyo, 153-8904, Japan. pa2022@art.osaka-med.ac.jp. Hauptthemen laut MEDLINE: Legislation, Drug.
Abstract (Originalsprache)
Scientists seldom know the differences between "rejected invention", "non-invention", "incomplete invention", "invention yet to be completed" and "defective invention". The Japanese Supreme Court appointed me as a specialist member (Article 92-2, Code of Civil Procedure) of intellectual property division for medical and biological patents. Herein, I present scientists to the differences and which of them are patentable. In order to prevent oneself from being taken for granted for the scientists' noblesse oblige by clever business administrations, the scientists must know the borderline between patentable or non-patentable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Tokyo, Rm670, Bldg4, RCAST, 4-6-1 Komaba, Meguro, Tokyo, 153-8904, Japan. pa2022@art.osaka-med.ac.jp
Zitieren
APA
Hisa, T. (2007). Incomplete Invention of Drugs. Recent Patents on Inflammation & Allergy Drug Discovery. https://doi.org/10.2174/187221307779815138
Vancouver
Hisa T. Incomplete Invention of Drugs. Recent Patents on Inflammation & Allergy Drug Discovery. 2007. doi:10.2174/187221307779815138
BibTeX
@article{Hisa2007,
author = {Hisa, Tomoyuki},
title = {Incomplete Invention of Drugs},
journal = {Recent Patents on Inflammation & Allergy Drug Discovery},
year = {2007},
doi = {10.2174/187221307779815138}
}
EUVIMED